Hemophilia A treatment scenario before the launch of HEMLIBRA
Despite the ups and downs throughout history, the management of hemophilia A patients substantially improved over the past 40 years. The groundbreaking discovery of cryoprecipitate in 1964 marked the beginning of the modern progression of hemophilia treatments. A few years later, researchers found that plasma-derived factor concentrates on FVIII products. Many hemophilia A drugs that were simpler to use than cryoprecipitate or fresh-frozen plasma were approved under this category, including FEIBA (Pfizer), MONOCLATEP (CSL Behring), and HEMOFIL-M (Baxter). Recombinant therapy development in the 1980s alte...
